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Abstract: The recent emergence of resistance to colistin, an antibiotic of last resort with dose-limiting
toxicity, has highlighted the need for alternative approaches to combat infection. This study
aimed to generate and characterise alginate oligosaccharide (“OligoG”)–polymyxin (polymyxin B
and E (colistin)) conjugates to improve the effectiveness of these antibiotics. OligoG–polymyxin
conjugates (amide- or ester-linked), with molecular weights of 5200–12,800 g/mol and antibiotic
loading of 6.1–12.9% w/w, were reproducibly synthesised. In vitro inflammatory cytokine
production (tumour necrosis factor alpha (TNFα) ELISA) and cytotoxicity (3-(4,5-dimethylthiazol-
2-yl)-2,5-diphenyltetrazolium bromide (MTT) of colistin (2.2–9.3-fold) and polymyxin B (2.9–27.2-fold)
were significantly decreased by OligoG conjugation. Antimicrobial susceptibility tests (minimum
inhibitory concentration (MIC), growth curves) demonstrated similar antimicrobial efficacy of ester-
and amide-linked conjugates to that of the parent antibiotic but with more sustained inhibition of
bacterial growth. OligoG–polymyxin conjugates exhibited improved selectivity for Gram-negative
bacteria in comparison to mammalian cells (approximately 2–4-fold). Both OligoG–colistin conjugates
caused significant disruption of Pseudomonas aeruginosa biofilm formation and induced bacterial death
(confocal laser scanning microscopy). When conjugates were tested in an in vitro “time-to-kill” (TTK)
model using Acinetobacter baumannii, only ester-linked conjugates reduced viable bacterial counts
(~2-fold) after 4 h. Bi-functional OligoG–polymyxin conjugates have potential therapeutic benefits in
the treatment of multidrug-resistant (MDR) Gram-negative bacterial infections, directly reducing
toxicity whilst retaining antimicrobial and antibiofilm activities.
Keywords: gram-negative bacteria; multidrug resistance; polymer therapeutics; colistin; polymyxin B
1. Introduction
Antimicrobial resistance (AMR) is a significantly growing global challenge that is associated
with elevated morbidity and mortality rates, high healthcare costs and >700,000 deaths annually [1,2].
Excessive use of antibiotics in animal husbandry, agriculture, and human and veterinary medicine
has contributed to a dramatic increase in life-threatening multi- and pan-drug resistant bacterial
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infections [3]. This environmental exposure has been compounded by decreases in the development
of novel antimicrobials and it has been predicted that AMR could result in 10 million annual deaths
by 2050 [4]. According to the World Health Organisation (WHO), Gram-negative bacteria such
as carbapenem-resistant Pseudomonas aeruginosa and Acinetobacter baumannii, extended spectrum
β-lactamase-producing and carbapenem-resistant Klebsiella pneumoniae and Escherichia coli represent a
major clinical threat and burden to public health [5]. It has been estimated that Gram-negative bacterial
resistance resulted in 960,000 hospital admission days in Europe in 2017 [6].
Polymyxins (Scheme 1), such as polymyxin B and colistin (polymyxin E), are a potent class of
polypeptide antibiotics. Despite the clinical efficacy of colistin against Gram-negative bacteria, it is
recommended for employment as an antibiotic of last resort, both to avoid resistance and, importantly,
due to dose-limiting nephro- and neurotoxicity [7]. To reduce this toxicity and optimise antimicrobial
activity, drug absorption and target specificity, several novel derivatives of polymyxin antibiotics are
being developed [8–11]. Structural modifications have involved the N-terminal fatty acyl moiety or
Dab side chains and demonstrated the importance of Dab at residue five in antimicrobial activity [12].
Progression to clinical trials of these polymyxin derivatives has, however, been limited due to their
narrow spectrum of antimicrobial activity, and their cytotoxicity/poor tolerability in animal studies [13].
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Scheme 1. Graphic structure of (a) colistin and (b) polymyxin B. The hydrophilic heptapeptide ring is
linked to a hydrophobic acyl tail through a tripeptide fragment. The only structural difference between
both molecules is an amino acid residue at position 6: d-leucine in colistin is replaced by d-phenylalanine
in polymyxin B. Composition of the fatty acyl tail: 6-methyloctanoic acid for polymyxin B1/E1 and
6-methylheptanoic acid for polymyxin B2/E2.
Polymer therapeutics have emerged as a promising strategy to combat antimicrobial resistance,
particularly when used to reinstate “old” antibiotics [14]. Conjugation of an antibiotic to a
water-soluble polymer offers many advantages compared to small molecule drugs, including reduced
toxicity/immunogenicity, prolonged plasma half-life and improved pharmacodynamic targeting
through the enhanced permeability and retention (EPR) effect [15]. Colistin has previously been
conjugated to both, dextrin [16] and poly(ethylene glycol) (PEG) [17], however, complete restoration
of antibiotic activity was not achieved after amylase-unmasking of dextrin–colistin conjugates,
presumably due to the presence of oligosaccharides attached to the colistin amine groups [18]. The use
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of alternative conjugation chemistry may offer the opportunity to optimise reinstatement of antibiotic
activity at sites of infection/inflammation [19]. Moreover, conjugation of the antibiotic to bioactive
polysaccharides affords the opportunity to deliver anti-infective bi-functional polymer therapeutics.
Although alginates, like dextrin, are recognised as non-toxic by the Food and Drug Administration
(FDA), their large molecular weight and lack of mammalian, alginate-degrading enzymes has limited
their use in protein/peptide conjugation. More recently, a low molecular weight alginate oligosaccharide
(OligoG, Mn 3200 g/mol), was extracted as a sodium salt from marine algae (Laminaria hyperborea)
with >85% of residues being composed of α-L-guluronic acid. Although OligoG has no (MIC) value,
it inhibits bacterial growth, adherence and biofilm development, and potentiates the activity of
antibiotics against Gram-negative MDR pathogens [20–24]. This low molecular weight alginate also
possesses hydroxyl and carboxyl functional groups that can be used for drug conjugation.
We hypothesised that conjugation of guluronic-rich, low molecular weight alginates to antibiotics,
such as polymyxins, could create a bi-functional antibiotic polymer therapeutic [25]; combining the
antimicrobial properties of both the antibiotic and the alginate, while simultaneously reducing systemic
toxicity of the antibiotic, and facilitating size-dependent targeting by the EPR effect at the site of
infection. Polymyxins were chosen as a model drug because previous studies have demonstrated that
OligoG can enhance the antimicrobial efficacy of colistin against MDR, Gram-negative P. aeruginosa
both in vitro and in vivo [26].
The aim of the study was to generate and characterise a bi-functional polymyxin conjugate
using OligoG to optimise the antimicrobial function of these last resort antibiotics. A range of
OligoG-polymyxin conjugates were synthesised and their physicochemical properties, in vitro
cytotoxicity and biological activity characterised. Antimicrobial activity was assessed using MIC assays,
growth curves, confocal laser scanning microscopy (CLSM) imaging and “time-to-kill” (TTK) studies.
2. Materials and Methods
2.1. Materials
OligoG CF-5/20 and the high molecular weight alginate PRONOVA UP MVG (>60% guluronic acid
and Mw of 200,000 g/mol) were provided by AlgiPharma AS (Sandvika, Norway). The LIVE/DEAD®
BaclightTM Bacterial Viability kit was from Invitrogen Molecular Probes (Paisley, UK). Pullulan gel
filtration standards were from Polymer Laboratories (Church Stretton, UK). All chemicals were obtained
from either Fisher Scientific (Loughborough, UK) or Sigma-Aldrich (Poole, UK) unless otherwise stated
and were of analytical grade.
2.2. Cell Lines and Cell Culture
Human kidney proximal tubule cells (HK-2) were obtained from the American Type Culture
Collection (ATCC) (Manassas, VA, USA) and screened to be free of mycoplasma contamination before
use. Keratinocyte serum-free (K-SFM) medium (with l-glutamine), bovine pituitary extract (BPE,
0.05 mg/mL), human recombinant epidermal growth factor (EGF, 5 ng/mL), 0.05% w/v trypsin-0.53 mM
ethylenediaminetetraacetic acid (EDTA) were from Invitrogen Life Technologies (Paisley, UK).
2.3. Bacterial Isolates and Growth Media
The bacterial strains (Table S1) used have been previously described [20,27]. Bacteria were grown
on either tryptone soy agar (TSA) or blood agar (BA) plates supplemented with 5% v/v defibrinated
horse blood. Bacterial overnight cultures were grown in tryptone soy (TS) broth and Mueller–Hinton
(MH) broth was used for susceptibility testing. All media were from LabM (Bury, UK). Artificial sputum
(AS) medium was prepared as previously described by Pritchard et al. [24].
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2.4. Synthesis of OligoG–Polymyxin Conjugates
To synthesise amide (A)-linked conjugates (Scheme 2a), OligoG (1000 mg, 0.3 mmol),
1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride (EDC; 96.8 mg, 0.5 mmol) and
N-hydroxysulfosuccinimide (sulfo-NHS; 109.6 mg, 0.5 mmol) were dissolved under stirring (15 min at
21 ◦C) in distilled water (dH2O; 10 mL). To this, colistin sulphate (146.7 mg, 0.1 mmol) or polymyxin
B (144.4 mg, 0.1 mmol) was added followed by drop-wise addition of NaOH (0.5 M) until pH 8 was
reached. The reaction mixture was stirred for 2 h at 21 ◦C, then stored at −20 ◦C prior to purification.
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To synthesise ester (E)-linked conjugates (Scheme 2b), OligoG (1000 mg, 0.3 mmol),
N,N′-dicyclohexyl carbodiimide (DCC; 64.5 mg, 0.3 mmol), 4-dimethylaminopyridine (DMAP; 6.4 mg,
0.05 mmol) and colistin sulphate (146.7 mg, 0.1 mmol) or polymyxin B (144.4 mg, 0.1 mmol) were
dissolved while stirring overnight at 21 ◦C in anhydrous DMSO (10 mL). The reaction was stopped by
pouring the mixture into excess chloroform (~100 mL). Formed precipitates were collected by filtration
and dissolved in dH2O (10 mL), then stored at −20 ◦C prior to purification.
2.5. Purification of OligoG–Polymyxin C jugates
OligoG–polymyxin conjugates were purified from the reaction mixture by fast protein liquid
chromatography (FPLC) using an AKTA Purifier system (GE Healthcare; Amersham, UK) connected
to a prepacked Superdex 75 16/600 GL column with a UV detector and a fraction collector (Frac-950).
Data analysis was performed using Unicorn 5.31 software (2011; GE Healthcare; Amersham, UK).
Samples (2 mL) were injected into a 2 mL loop using phosphate buffered saline (PBS) buffer (pH 7.4) as
a mobile phase at 1 mL/min. Fractions were collected, pooled and lyophilised. Then, conjugates were
re-dissolved in a minimal volume of dH2O and dialysed (1000 g/mol cut-off) against 5 × 1 L dH2O to
remove PBS salts. The final conjugates were lyophilised and stored at −20 ◦C.
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2.6. Characterisation of OligoG–Polymyxin Conjugates
Size exclusion chromatography with multi-angle light scattering detection (SEC-MALS) or
refractive index detection (SEC-RI), were used to measure the approximate molecular weight and
polydispersity of the conjugates. SEC-MALS was performed at ambient temperature on an HPLC
system consisting of a solvent reservoir, on-line degasser, automatic sample injector, HPLC isocratic
pump, pre-column and serially connected columns (TSKgel 4000 and 2500 PWXL). The column outlet
was connected to a Dawn HELEOS-II multi-angle laser light scattering photometer (Wyatt, MO, USA)
(λ0 = 663.8 nm) followed by a Shodex RI-501 RI detector. The eluent was 0.15 M NaNO3 with 0.01 M
EDTA, pH 6.0 and the flow rate was 0.5 mL/min. Samples (10 mg/mL) were filtered (pore size 0.45 µm)
before injection and analysed twice with injection volumes of 25 and 50 µL. A weighted specific
refractive index increment (dn/dc) value was calculated from the % w/w colistin using dn/dc = 0.150
and 0.185 for alginate and colistin, respectively. Data were collected and processed using the Astra
software (version 7.3.0; Wyatt, USA).
The SEC-RI system consisted of two TSK gel columns (G5000PWXL and G3000PWXL) (Tosoh,
Germany) in series connected to a Gilson 133 differential refractometer (Middleton, WI, USA).
Samples were prepared in PBS (3 mg/mL) and eluted using PBS (pH 7.4) as the mobile phase at a flow
rate of 1 mL/min. Cirrus GPC software (version 3.2, 2006) from Polymer Laboratories (Church Stretton,
UK,) was used for data analysis. Molecular weight was determined relative to pullulan molecular
weight standards.
The FPLC system described above, connected to a Superdex 75 (10/300 GL) column, was also used
to assess conjugate purity. Samples (3 mg/mL in PBS) were injected into a 100 µL loop at 0.5 mL/min.
The area under the curve was used to estimate the percentage of free and conjugated antibiotic.
The total polymyxin content of conjugates was determined by bicinchoninic acid (BCA) assay using
colistin sulphate or polymyxin B standards.
Before and after OligoG conjugation, the number of available primary amine groups on colistin
and polymyxin B was determined using the ninhydrin assay. First, a lithium acetate buffer (4 M)
was prepared by dissolving lithium acetate dihydrate 40.81% w/v in dH2O. Acetic acid (glacial) was
added to reach pH 5.2 before adjusting the final volume. Next, ninhydrin reagent was prepared by
dissolving ninhydrin 2% w/v and hydrindantin 0.3% w/v in 7.5 mL of DMSO and 2.5 mL of lithium
acetate buffer. Test compounds (86 µL) were diluted with ninhydrin reagent (1:1) and heated in a water
bath (100 ◦C) for 15 min. Samples were subsequently cooled to room temperature and mixed with
50% v/v ethanol solution (130 µL). Then, aliquots (100 µL) were transferred into the wells of a 96-well
microtitre plate and analysed spectrophotometrically at 570 nm. Calibration of the assay was achieved
using ethanolamine (0–0.1158 mM).
NMR spectroscopy was used to confirm OligoG–polymyxin conjugation (Supplementary Materials).
2.7. Drug Release of OligoG–Polymyxin Conjugates
To compare the rate of degradation of OligoG–polymyxin conjugates, solutions were prepared
(3 mg/mL) in either (i) PBS at pH 5, (ii) PBS at pH 7, or (iii) PBS at pH 7 containing alginate lyase from
Sphingobacterium multivorum (1 U/mL) and incubated at 37 ◦C for 0, 2, 4, 6, 24 and 48 h. Upon collection,
samples were immediately snap-frozen in liquid nitrogen and stored at−20 ◦C. Time-dependent changes
in molecular weight and free polymyxin content were determined by SEC-RI and FPLC, respectively.
2.8. Characterisation of In Vitro Toxicity
A 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay was used to measure
cell viability and proliferation of HK-2 cells. Cells were seeded into sterile 96-well microtitre plates
at 1 × 105 cells/mL (100 µL/well) and allowed to adhere for 24 h at 37 ◦C. The following day, the old
medium was replaced with test compounds (0–1 mg/mL polymyxin base) dissolved in filter-sterilised
K-SFM. After 67 h incubation at 37 ◦C, filter-sterilised MTT solution (20 µL of a 5 mg/mL solution in
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PBS) was added to each well and incubated for a further 5 h at 37 ◦C. Finally, the medium was carefully
removed, and the formazan crystals were solubilised in DMSO (100 µL) for 30 min. Absorbance was
measured at 550 nm using a Fluostar Omega microplate reader. The results are stated as percentage
cell viability compared with the untreated control cells. Data are expressed as mean ± SEM (n = 18).
Release of the cytokine, tumour necrosis factor alpha (TNFα), by HK-2 cells (1 × 105 cells/mL) after
exposure to free- and OligoG-conjugated antibiotic (0–1 mg/mL polymyxin base) was assessed using
an enzyme-linked immunosorbent assay (ELISA) kit. After 72 h incubation, the 96-well microtitre
plates were centrifuged (226× g, 3 min), the supernatant was collected, diluted with reagent diluent
(1:1) and analysed with the TNFα ELISA kit according to the manufacturer’s instructions (Fisher
Scientific; Loughborough, UK). Plates were analysed spectrophotometrically at 450 nm. In parallel,
100 µL of K-SFM was added to the wells of the centrifuged plates containing cells and MTT assays
were performed. A standard curve was used to calculate TNFα concentrations in the test samples,
which were then multiplied by the dilution factor (×2) and divided by cell viability for each drug
concentration (from the MTT assay). Two outliers were identified and removed using robust regression
and the outlier removal (ROUT) method (Q coefficient = 0.2%). Data are expressed as mean ± SEM (n = 6).
2.9. Antimicrobial Activity of OligoG–Polymyxin Conjugates
The minimum inhibitory concentration (MIC) of colistin (as sulphate salt) and polymyxin B and
their conjugates was determined using the broth microdilution method in MH broth in accordance
with standard guidelines [28]. Test organisms were suspended in MH broth (100 µL, 5 × 105 colony
forming units (CFU)/mL) and incubated in 96-well microtitre plates in serial two-fold dilutions of the
test compounds. The MIC was defined as the lowest concentration of test compound that produced no
visible growth after 16–20 h. Results were expressed as mode (n = 3). For the purpose of calculating
selectivity index (SI), MIC values lower than 0.008 were taken as the lowest concentration tested.
Selective activities of the polymyxins and OligoG–polymyxin conjugates were calculated as follows:
Selectivity index (SI) = IC50 (µg/mL)/MIC (µg/mL).
To investigate whether alginate oligomer degradation is required for antimicrobial activity,
MIC assays were also conducted in the presence of alginate lyase (1 and 10 U/mL), whereby alginate
lyase was added to the MH broth during microtitre plate set up. In addition, alginate oligomer–colistin
conjugates (3 mg/mL) were incubated in PBS at pH 7 containing bacterial alginate lyase (1 and 10 U/mL)
at 37 ◦C for 24 h, before preparing microtitre plates as described above.
To more closely mimic in vivo environmental conditions, the antimicrobial activity of test
compounds was studied in the presence of mucin, by supplementing MH broth with porcine stomach
(type II) mucin (0.2 and 2% w/v) and used to set up the 96-well plates according to the standard MIC
protocol. To account for turbidity caused by mucin, resazurin dye solution (30 µL, 0.01% w/v in dH2O)
was added to each well and incubated for a further 3 h at 37 ◦C. Colour changes were observed
and recorded.
To study the antimicrobial efficacy of test compounds under more clinically relevant conditions,
the MIC protocol was performed using AS medium instead of MH broth. The plates were incubated
with resazurin as described above.
A checkerboard assay was used to assess synergy of test compounds with azithromycin dihydrate.
Here, stock solutions of test compounds (8 × MIC) and serial two-fold dilutions of azithromycin
dihydrate (16–1/16 ×MIC) were freshly prepared in MH broth. Test compound solutions (100 µL) were
placed in the wells of row 1, then serially diluted along the ordinate with MH broth. Serially diluted
azithromycin dihydrate solutions (50 µL) were then added to the wells in decreasing concentration
along the abscissa. Each microtitre well was inoculated with the test organism (5 × 105 CFU/mL) and
incubated at 37 ◦C for 20 h. The fractional inhibitory concentration index (FICI) was calculated by
comparing the MIC values of the individual agents with the MIC value of the combined treatments [29].
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Drug combinations were considered synergistic when the mean FICI was ≤0.5, additive when the FICI
was between 0.5 and 2, indifferent when the FICI was between 2 and 4, and antagonistic when the FICI
was ≥4 [30]. Results were expressed as median values (n = 3).
To study the effect of test compounds on bacterial pharmacokinetic profiles, 96-well microtitre
plates were set up according to the standard MIC protocol, then placed in a Fluostar Omega Microplate
Reader at 37 ◦C, and absorbance at 600 nm was measured hourly for 48 h. Results were expressed
as mean values (n = 3). Unconjugated colistin plus OligoG, OligoG and the high molecular weight,
biologically inactive alginate, PRONOVA, at equivalent concentrations used in amide-linked or
ester-linked conjugates, were used as controls.
2.10. Anti-Biofilm Activity of OligoG–Polymyxin Conjugates
To analyse the effect of test compounds on biofilm formation, solutions of test compounds in
MH broth were inoculated (1:10) with P. aeruginosa R22 (standardised to 107 CFU/mL) in a Greiner
glass-bottomed optical 96-well plate. The plate was then wrapped in parafilm and incubated (37 ◦C,
20 rpm) for 24 h. The supernatant was carefully removed and replaced with 10% v/v LIVE/DEAD
stain in PBS prior to imaging. CLSM of Syto 9 (λex/λem maximum, 480/500 nm) and propidium iodide
(λex/λem maximum, 490/635 nm) was performed using a Leica SP5 confocal microscope with ×63 lens
(under oil) and a step size of 0.79 µm. Z-stack CLSM images were analysed using COMSTAT image
analysis software [31] and results were expressed as mean ± SEM (n = 15).
2.11. Pharmacokinetic–Pharmacodynamic (PK–PD) Model
A two-compartment static dialysis bag model (adapted from Azzopardi et al. [32]) was used to study
the PK–PD profile of OligoG–colistin conjugates. First, the ability of the dialysis membrane to control
diffusion of test compounds was assessed. The inner compartment (IC) contained OligoG–colistin or
colistin sulphate (10 mg/mL colistin base; 5 mL) in PBS and the outer compartment (OC) contained
sterile PBS (15 mL). The aseptically sealed beaker was incubated (37 ◦C, 70 rpm) for 48 h. Samples were
collected at various time points from each compartment and stored at −20 ◦C prior to analysis of
colistin content by BCA assay.
A modified experimental set-up was used to investigate the concentration- and time-dependent
antimicrobial activity of test compounds using a TTK assay (48 h). Here, the total volume in the
system was considered, with the IC containing test compounds at MIC (colistin sulphate 0.25 µg/mL;
OligoG–A–colistin 0.125 µg/mL colistin base; OligoG–E–colistin 0.125 µg/mL colistin base) or 2 ×MIC
(OligoG–A–colistin 0.25 µg/mL colistin base; OligoG–E–colistin 0.25 µg/mL colistin base) in PBS.
The OC contained MH broth inoculated with A. baumannii 7789 (5 × 105 CFU/mL). Samples were
collected from the OC (0, 2, 4, 6, 24 and 48 h) and colony counts (CFU/mL) determined using
drop counts. Treatments were considered bactericidal if the reduction in viable bacterial counts
was ≥3 log10 CFU/mL (equivalent to 99.9% of the initial inoculum) and bacteriostatic if the decrease
was <3 log10 CFU/mL [33,34]. Growth (no test compounds) and sterility (no bacteria) controls were
also performed.
2.12. Statistical Analysis
GraphPad Prism (version 6.01, 2012; San Diego, CA, USA) was used for statistical analysis.
Statistical significance was indicated by *, where * p < 0.05, ** p < 0.01, *** p < 0.001 and **** p < 0.0001.
Analysis of variance (ANOVA) was used to evaluate multiple group comparisons (n ≥ 3) followed by
Dunnett’s post hoc test to account for multiple comparisons.
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3. Results
3.1. Synthesis and Characterisation of OligoG–Polymyxin Conjugates
The characteristics of the OligoG–antibiotic conjugates synthesised in this study are summarised
in Table 1 and Table S2. Polymyxin B conjugates typically showed less drug loading (6.1–8% w/w)
than the colistin conjugates (8.1–12.9% w/w). SEC-MALS, SEC-RI and FPLC analysis confirmed the
presence of high molecular weight conjugates with <6% unbound drug (Figures S1 and S2, Table S3).
The mean molecular weight of amide- and ester-linked conjugates (measured by SEC-MALS) was
8200–12,800 g/mol and 5200–6200 g/mol, respectively. The ninhydrin assay indicated that 2–4 amine
groups were used for binding to OligoG via amide conjugation. Diffusion-ordered spectroscopy
(DOSY) NMR confirmed covalent coupling of OligoG to colistin. Signals corresponding to OligoG and
colistin in the samples had the same diffusion coefficient (1.26 × 10−10 m2/s), indicative of covalent
coupling (Figure S3). OligoG–A–colistin conjugate samples appeared to contain some free OligoG
while the DOSY spectrum for OligoG–E–colistin conjugate showed the presence of both, free OligoG
and colistin in the sample.
Table 1. Summary of the properties of the OligoG-polymyxin conjugates synthesised in this study.
Tested
Compound
Mw (g/mol)
(PDI)
by SEC-MALS
Polymyxin
Content
(% w/w)
Molar Ratio
(per Colistin)
Conjugated
NH2 per
Molecule
Free
Polymyxin
(%)
OligoG–A–colistin
Mean 9220 (1.3) 9.4 4.3 3.4 3.2
Range 8200–12,300 (1.2–1.4) 8.1–12.5 3.1–5.0 2.7–4.6 1.5–5.7
OligoG–E–colistin
Mean 5550 (1.3) 10.9 3.8 N/A 2.7
Range 5200–5900 (1.2–1.3) 8.3–12.9 3.0–4.9 N/A 2.0–3.5
OligoG–A–polymyxin B
Mean 10,950 (1.4) 7.1 6.0 2.0 1.6
Range 9100–12,800 (1.3–1.5) 6.1–8.0 5.1–6.8 1.9–2.0 1.6
OligoG–E–polymyxin B 6200 (1.2) 7.0 5.9 N/A 2.7
Abbreviations: A, amide; E, ester; PDI, polydispersity index (given in brackets); SEC-MALS, size exclusion
chromatography with multi-angle light scattering detection; N/A, not applicable.
3.2. Stability of OligoG–Polymyxin Conjugates
Both ester- and amide-linked conjugates of OligoG–colistin and OligoG–polymyxin B incubated
in PBS at either pH 5 or pH 7 showed no significant decrease in molecular weight (Figure S4).
Conjugates were slightly less stable at pH 7, compared to pH 5. Conversely, alginate lyase effectively
triggered ~30% of colistin and ~90% of polymyxin B release (increase in % free drug) within 24 h
from these conjugates at 1 U/mL. There was little difference in total drug release between amide- and
ester-linked conjugates.
3.3. Cytotoxicity of OligoG–Polymyxin Conjugates
The concentration-dependent cytotoxicity of unmodified antibiotics, OligoG and OligoG-
polymyxin conjugates in HK-2 cells is shown in Figure 1. OligoG was not cytotoxic at
<10 mg/mL. Cytotoxicity was greatest for the free drugs (colistin sulphate half maximal inhibitory
concentration (IC50 = 0.026 mg/mL), polymyxin B (0.011 mg/mL)); slightly reduced by ester
conjugation (OligoG–E–colistin (IC50 = 0.057 mg/mL), OligoG–E–polymyxin B (0.032 mg/mL));
and significantly reduced for the amide-linked conjugates (OligoG–A–colistin (IC50 = 0.242 mg/mL),
OligoG–A–polymyxin B (0.299 mg/mL)). ELISA showed that the unmodified antibiotics induced
greater TNFα release than the conjugates (Figure 1c). OligoG–E–polymyxin B caused the highest
release of TNFα, compared to the other conjugates, but this was still lower than the unmodified drug.
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Figure 1. In vitro cytotoxicity of OligoG–polymyxin conjugates in human kidney proximal tubule cells
(HK-2) cells. Cell viability determined by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
(MTT) assay after 72 h incubation. (a) Colistin sulphate. (b) Polymyxin B. Data are presented as mean %
of untreated control ± SEM (n = 18). (c) Tumour necrosis factor alpha (TNFα) release in HK-2 cells after
incubation with OligoG–polymyxin conjugates for 72 h (±SEM; n = 6). (d) Half maximal inhibitory
concentration (IC50) values (±SEM) and fold-change (MTT assay) of tested compounds in HK-2 cells.
Significance is indicated by *, where * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001 compared to
colistin sulphate or polymyxin B controls. Abbreviations: A, amide; E, ester.
3.4. Antimicrobial Activity of OligoG–Polymyxin Conjugates
The effects of conjugation on antimicrobial efficacy against a range of Gram-negative pathogens
varied between the conjugates a d antibiotic (Table 2). Whilst ester-conjugation resulted in similar
(≤2-fold differences) or decr ased MIC values for OligoG–coli tin and –polymyxin B co jugates,
the amide-linked conjugates demonstrated increased MIC values. This effect was parti ularly evident
for th polymyxi B conjugates, where MICs were increased by 4- to 32-fold. OligoG conjugation did n t
impr ve the bactericidal efficacy of colistin in colistin-resistant strains (Table 2). Both OligoG–polymyxin
conjugates xhibited substanti lly improved sele tivity for Gram-negative bacteria in comparison
to mammalia cells, compar to unmodified colistin sulphate (1.7–4.7-fold) and polymyxin B
(2.3–4.1-f ld) (Table S4).
The antimicrobial activity of the conjugates was also assessed in the presence of alginate lyase or
following pre-incubation with alginate lyase (Table S5), where no significant change was observed for
either amide- or ester-bonded conjugates.
In contrast, wh n muci was added to the broth, antimicrobial activity of OligoG–polymyxin
conjugates decreased in a dose-depen nt manner (Table S6). The presence of unconjugated OligoG
with colistin sulphate or polymyxin B did ot alter the antimicrobial activity of the free a tibiotic.
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Table 2. Minimum inhibitory concentration (MIC) determinations of OligoG–polymyxin conjugates against a range of Gram-negative bacterial pathogens.
Isolate
Tested Compound MIC (µg/mL Drug Base)
Colistin Sulphate Polymyxin B OligoG–E–Colistin OligoG–E–Polymyxin B OligoG–A–Colistin OligoG–A–Polymyxin B
P. aeruginosa R22 0.5 0.25 1 0.25 2 4
P. aeruginosa MDR 301 0.5 0.5 0.5 0.5 1 2
P. aeruginosa NH57388A 0.25 0.25 0.25 0.25 0.5 1
P. aeruginosa NCTC 10662 0.125 0.063 0.25 0.25 1 4
K. pneumoniae KP05 506 0.125 0.125 0.125 0.25 0.125 0.5
K. pneumoniae IR25 0.063 0.125 0.125 0.125 1 4
A. baumannii MDR ACB 0.5 0.125 0.25 0.063 1 2
A. baumannii 7789 0.25 0.125 0.125 0.5 0.125 0.5
E. coli AIM-1 <0.008 <0.004 0.008 0.016 0.008 0.063
E. coli IR57 0.125 0.5 0.25 0.5 0.125 2
E. coli 5702 0.031 0.063 0.031 0.063 0.063 0.25
E. coli NCTC 10418 0.125 0.25 0.5 0.25 0.25 4
E. coli PN21 8 8 16 8 32 32
E. coli PN25 8 4 8 4 32 32
E. coli PN26 0.125 0.125 0.25 0.25 0.5 0.5
E. coli ATCC 25922 0.25 0.5 1 0.5 1 16
Increased antimicrobial activity of conjugated polymyxin (MIC ≥ 1-fold lower compared to colistin sulphate or polymyxin B controls) is shown in bold. Abbreviations: A, amide; E, ester.
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Differences in antimicrobial activity of both, free- and OligoG-bound antibiotics were observed
in AS medium compared to MH broth (Table S7). In most cases, using the checkerboard assay,
an indifferent or additive effect was observed when azithromycin dihydrate was combined with
OligoG–colistin or colistin sulphate (Table S8). Generally, OligoG conjugation did not alter the efficacy
of the antibiotic combination, except for A. baumannii 7789, where the additive effect of colistin sulphate
+ azithromycin dihydrate (FICI = 1.14) became indifferent when azithromycin dihydrate was combined
with OligoG–colistin conjugates (FICI >2.5). However, the combination of azithromycin dihydrate
with OligoG–E–colistin resulted in a synergistic effect for the E. coli National Collection of Type Culture
(NCTC) 10418 isolate (FICI = 0.46).
Bacterial growth curves of P. aeruginosa MDR 301 (Figure 2) showed that the OligoG–colistin
conjugates delayed bacterial growth in a concentration-dependent manner (indicated by the longer
lag-phase), and exponential growth was similarly slower compared to the untreated control.
Growth inhibition (up to >48 h) was noted for the OligoG–colistin conjugates at ≥2 ×MIC, while higher
equivalent concentrations of colistin sulphate were required (≥8 × MIC) to achieve comparable
efficacy. Neither amide- nor ester-linked conjugates had an effect on time to onset of bacterial
growth. Both, OligoG–A–colistin and OligoG–E–colistin conjugates, at their MIC (1 and 0.5 µg/mL
colistin base, respectively), demonstrated a delayed lag phase of >24 h and >18 h, respectively.
Typically, colistin covalently conjugated to OligoG showed similar activity to the combined mixture
of unconjugated colistin and OligoG at equivalent concentrations. Furthermore, neither OligoG nor
Pronova alone had any significant effect in reducing bacterial growth, when an equivalent concentration
to that contained in OligoG–colistin conjugates was used.
3.5. Anti-Biofilm Activity of OligoG–Polymyxin Conjugates
CLSM of biofilms grown in the presence of free and OligoG-bound colistin (≥MIC) showed a
marked effect on biofilm formation (Figure 3). For example, the OligoG–E–colistin conjugate, at its MIC
(1 µg/mL colistin base), caused obvious bacterial clumping, disruption of biofilm structure, and cell
death (as noted by increased numbers of red cells). COMSTAT analysis revealed a significant reduction
in biofilm thickness for all treatments (≥MIC) (p < 0.05) and biofilm roughness was significantly
increased by OligoG–colistin conjugates (≥MIC) and colistin sulphate (MIC) treatments (p < 0.05).
Both OligoG–colistin conjugates (2×MIC) significantly reduced biofilm biomass compared to untreated
control (p < 0.05), whereas no significant change was observed with colistin sulphate (up to 2 ×MIC).
3.6. Pharmacokinetic–Pharmacodynamic (PK–PD) Model
In the PK-PD model (Figure 4), when antibiotic was placed in the IC, colistin diffused more rapidly
than the OligoG–colistin conjugates (1 mg/mL in the OC was reached at 2.83 h (colistin) < 10.47 h
(OligoG–E–colistin) < 17.35 h (OligoG–A–colistin)). Colistin sulphate, at MIC (0.25 µg/mL) and the
OligoG–E–colistin conjugate at 2 ×MIC (0.25 µg/mL colistin base) caused substantial bacterial killing
after 4 h (<3 log10 CFU/mL) (Figure 4b). Both treatments caused a reduction in viable bacterial counts
compared to the control (~5-fold lower) and the initial starting bacterial concentration (~2-fold lower).
However, no antimicrobial effect was observed with the OligoG–A–colistin conjugate up to 2 ×MIC.
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Figure 2. Bacterial growth curves for P. aeruginosa MDR 301 (48 h) in the presence of the following
antimicrobials. (a) OligoG–A–colistin conjugate. (b) OligoG–E–colistin conjugate. (c) Colistin sulphate.
(d) Colistin sulphate plus OligoG control for amide-linked conjugate. (e) OligoG control for amide-linked
conjugate. (f) PRONOVA control for amide-linked conjugate. (g) Colistin sulphate plus OligoG control
for ester-linked conjugate. (h) OligoG control for ester-linked c njugate. (i) PRONOVA control for
ester-linked conjugate. Controls were used at the equivalent concentrations used in the corresponding
amide- or ester-linked conjugates (n = 3). Abbreviations: A, amide; E, ester.
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Figure 3. Biofilm formation assay showing LIVE/DEAD (green/red, respectively) stained confocal laser scanning microscopy (CLSM) images (aerial and cross-
sectional views, scale bar, 35 μm) of P. aeruginosa R22 biofilms grown for 24 h in the presence of (a) OligoG–A–colistin (MIC, 2 μg/mL colistin base), (b) OligoG–E–
colistin (MIC, 1 μg/mL colistin base) and (c) colistin sulphate (MIC, 0.5 μg/mL colistin base). Corresponding COMSTAT analysis of the CLSM images is also shown 
(± SEM; n = 15). Significance is indicated by *, where * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001 compared to an untreated control. 
Figure 3. Biofilm formation assay showing LIVE/DEAD (green/red, respectively) stained confocal laser scanning microscopy (CLSM) images (aerial and cross-sectional
views, scale bar, 35 µm) of P. aeruginosa R22 biofilms grown for 24 h in the presence of (a) OligoG–A–colistin (MIC, 2 µg/mL colistin base), (b) OligoG–E–colistin (MIC,
1 µg/mL colistin base) and (c) colistin sulphate (MIC, 0.5 µg/mL colistin base). Corresponding COMSTAT analysis of the CLSM images is also shown (±SEM; n = 15).
Significance is indicated by *, where * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001 compared to an untreated control.
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Figure 4. Pharmacokinetic–pharmacodynamic (PK–PD) model to compare diffusion of free- and 
OligoG-conjugated colistin. (a) Change in colistin concentration in the outer compartment over 48 h 
(measured by BCA assay). Data are expressed as mean ± SD (n = 3). (b) Viability count of A. baumannii 
7789 in a “time-to-kill” (TTK) model. Data represent mean colony forming units (CFU) ± SD (n = 3). 
Dotted line, lower limit of detection (102 CFU/mL). Abbreviations: A, amide; E, ester. 
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Furthermore, sugar residues and/or linker groups that remain attached to the antibiotic Dab residues 
after polymer degradation, may result in reduced antimicrobial activity, as observed with amide-
linked dextrin–colistin conjugates [18]. In parallel, ester-linked OligoG–polymyxin conjugates were 
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7789 in a “time-to-kill” (TTK) model. Data represent mean colony forming units (CFU) ± SD (n = 3).
Dotted line, lower limit of detection (102 CFU/mL). Abbreviations: A, amide; E, ester.
4. Discussion
4.1. Rationale for Development of OligoG–Polymyxin Conjugates
In recent years, interest in developing polymyxin derivatives to improve the therapeutic index
or provide activity towards bacterial strains that are not currently susceptible to polymyxins has
g own considerably [35]. Structural modifications, such as remova or substitution of the N-termin l
acyl chain, reduction in the number of positive charges, polymer c njuga ion and the introduction
of hydrophobic residues, have all been explored in an attempt to improve activity, reduce adverse
side effects and elucidate structur –activity relationships [36,37]. These s udies have demon trated
the ritical import nce of the amphipathicity f polymyxin molecule for their antimicrobial activity,
wh h stems from the c arged Dab residues and hydrophobic tai . This study compared the activity
and toxicity of OligoG–polymyxin conjugates containing reversible or irreversible linking c mistries,
to improve the therapeutic index of the p lymyxins.
To form an amide bond betw en OligoG and polymyxin antibiotics, the carboxyl groups of the
polymer were first activate y EDC in the presence of sulfo-NHS to reate a stable amine-reactiv
inter diate [38]. The resultant amine-reactiv sulfo-NHS ester was then bound to pri ary amines
on the polymyxins. We hypothes s d that amide-linked conjugates would rely on degradation
f t OligoG backbone by alginate ly se. There are n known mammalian enzymes capable of
degrading algi ate, but bact rial alginate lyase from K. pneu oniae and P. aeruginosa has be n fou d
in cys ic fibrosis patients’ lungs [39] and could provide an opportunity for site-specific release of a
therapeutic payload from an alginate conjugated drug. Although alginate lyas s from thes bacter a
are generally co sidered to be mannuronate-specific, it has be n shown that they may also d mo strate
moderat to low activity towards guluron te [40]. N n-biodegradable polym rs whose olecular
weight is below the renal th eshold (<40,000 g/mol) are expected to be readily excreted from he
ody [41], so the conjugates synthesised in th present study should b readily excreted by the kidney.
Furthermore, sugar residues and/or link r groups that remain attache to the an ibiotic Dab residues
after polym r de radation, m y result in reduced antimicrobial c ivity, as observed with amide-l nk d
dextrin–colistin conjugates [18]. In parallel, ster-linked Olig G–polymyxin conjugat s ere formed
using Steglich esterificati . Here, the polymer carboxyl groups were activated by DCC, with DMAP
as a catalyst [42]. The r ultant O-acylisourea intermediate was then bound to hydroxyl groups on the
polymyxins. Addition of DMAP as a ca alyst compensates for hydroxyls being p orer nucleophiles
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than amines (which can cause spontaneous rearrangement of the O-acylisourea intermediate into
undesirable N-acylurea) by reacting with O-acylisourea to form an acyl pyridinium species. Reaction of
DMAP with O-acylisourea forms an acyl pyridinium intermediate that is unable to form intramolecular
by-products but can react with a hydroxyl group to form an ester bond [43]. Ester-linkage permits
complete release of the native antibiotic at low or high pH, and by enzymatic activity and reactive
oxygen species at sites of infection [44]. Moreover, release of intact OligoG at the target site would
restore intrinsic antimicrobial activity of the polymer, which would further enhance its antibiotic
efficacy in vivo.
4.2. Physicochemical Characterisation of OligoG–Polymyxin Conjugates
Covalent attachment of OligoG to colistin was confirmed using several methods. DOSY is an
indirect method that can detect if the polymer and peptide are chemically linked as they will have
the same diffusion coefficient if bound together in solution [45] while SEC detects an increase in size
caused by an increase in molecular weight. In a control experiment using SEC-MALS, OligoG with
10% w/w added colistin yielded almost identical RI chromatograms as pure OligoG, confirming that the
observed shift in elution profile for the OligoG–colistin conjugates was not simply due to electrostatic
interactions between OligoG and free colistin. DOSY confirmed successful conjugation using both
amide and ester linkers. Nevertheless, DOSY also detected unbound colistin in the OligoG–E–colistin
sample and SEC-MALS analysis did not show an increased molecular weight compared to free OligoG.
This may be caused by hydrolysis of the ester linkage during measurement (in D2O at 25 ◦C), rather than
insufficient removal of unreacted material, highlighting the importance of using multiple analytical
methods to characterise these complex molecules.
4.3. Biological Characterisation of OligoG–Polymyxin Conjugates
Polymyxin antibiotics have been reported to cause severe nephrotoxicity in up to 53.5% of
patients [46] due to extensive reabsorption of the drug by renal tubular cells [47]. OligoG–polymyxin
conjugates in the present study exhibited a marked decrease in in vitro cytotoxicity in kidney cells
when compared to unmodified antibiotics. As expected, ester-linked polymyxin conjugates were
considerably more cytotoxic towards HK-2 cells compared to amide-linked conjugates. Since the
positively charged Dab residues are known to mediate polymyxin toxicity, and 2–4 of these primary
amines were used for irreversible (amide-linked) conjugation with OligoG, this result was unsurprising.
Antimicrobial efficacy of all OligoG–polymyxin conjugates was comparable to that of the parent
antibiotic. However, attachment of OligoG in the bi-functional molecule was unable to overcome
colistin resistance. For colistin-sensitive strains, conjugate MIC values were below the Clinical
and Laboratory Standards Institute [48] and European Committee on Antimicrobial Susceptibility
Testing [49] susceptibility breakpoints (≤2 µg/mL) for polymyxins. Importantly, ester-linked conjugates
showed full retention of the antimicrobial activity of the free drug, while the antimicrobial activity
of the amide-linked conjugates was reduced by more than two-fold, presumably because of residual
sugars and/or linker groups on the antibiotic amine groups. Although these studies did not test the
stability of the conjugates in bacterial growth medium, it is likely that hydrolysis of the ester bond
would occur during the MIC assay incubation. This may explain the smaller decrease in antimicrobial
activity seen with ester-linked conjugates compared to amide-linked ones. Greater selectivity of
OligoG–A–polymyxin conjugates for Gram-negative bacteria in comparison to mammalian cells
suggests better tolerability and reduced side effects in vivo and substantially improved efficacy at
clinically relevant concentrations compared to the free antibiotic. In addition, studies with alginate
lyase suggested that either OligoG degradation is not necessary for antibiotic activity, or that alginate
oligomers are broken down by bacterial enzymes. Nevertheless, compared to dextrin–colistin
conjugates described in previous studies [16], alginate oligomer–conjugates were significantly more
potent (more than five-fold change). This may be due to the larger molecular weight of dextrin causing
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steric hindrance or the charge difference between the two polymers, but more likely, it can be attributed
to the inherent biological activity of OligoG itself [20].
Sustained antibiotic release was demonstrated by slower bacterial growth in the presence of
OligoG–colistin conjugates, which was dose-dependent. In this study, lower concentrations of
OligoG–colistin conjugates, compared to free colistin, were required to inhibit bacterial growth which
was sustained for up to 48 h. OligoG–E–colistin delayed the onset of bacterial growth for much
longer than amide-linked conjugates, suggesting that, after systemic administration, OligoG–E–colistin
conjugates might achieve better therapeutic activity in vivo. Similarly, when PEG was attached to
colistin via a labile ester bond, sustained drug release led to equivalent or better antimicrobial activity
against A. baumannii and P. aeruginosa isolates [17].
In a clinical setting, binding of colistin to sputum biomolecules (e.g., mucin) in the airways could
negatively impact antibiotic effectiveness and availability. Indeed, Huang et al. [50] demonstrated
>100-fold increase in MIC values of both, colistin and polymyxin B, when mucin was added to the
bacterial culture medium. A four-fold increase in the MIC of colistin was also reported when the
assay was conducted in AS medium instead of MH broth, thought to be caused by bacterial growth
disruption, structural modifications of lipopolysaccharides or direct colistin–mucin interactions [24].
Although recent studies have demonstrated the ability of OligoG to bind mucin [51], conjugation of
OligoG to colistin and polymyxin B did not affect the ability of the antibiotic to bind mucin or alter the
effect of nutrient-deficient medium.
In practice, patients with severe infections of MDR pathogens are usually treated with combinations
of two or more antibiotics to overcome or prevent drug resistance. When we combined OligoG–colistin
conjugates with azithromycin dihydrate, an antibiotic that has previously shown enhanced efficacy in
combination with OligoG [20], antimicrobial activity of the drug was enhanced, but only additively.
Similarly, He et al. [52] reported additive effects in P. aeruginosa when they combined a low molecular
weight alginate oligosaccharide (Mw < 10 kDa) with azithromycin, suggesting that the alginate
oligosaccharide component of OligoG–colistin conjugates may be responsible for the additive effects
observed in our study.
Chronic airway infections by P. aeruginosa affect more than 80% of CF patients and contribute to a
progressive decline in lung function [53]. Marked disruption of P. aeruginosa biofilm formation was
observed when they were grown in the presence of both OligoG–colistin conjugates, although only the
ester-linked conjugate induced bacterial clumping (≥MIC) which might be associated with the higher
cationic charge of colistin. This is in keeping with the findings of Powell et al. [23] who showed that
OligoG, at concentrations ≥0.5%, caused P. aeruginosa aggregation, while higher concentrations (≥2%)
caused significant disruption of bacterial biofilm formation and growth.
4.4. PK–PD Modelling
Drug TTK profiles and colistin release rate from amide- or ester-linked OligoG–colistin conjugates
were investigated using an in vitro two-compartment PK–PD model. Predictably, diffusion of colistin,
which was mirrored by a time-dependent increase in drug concentration in the OC, was substantially
faster than the OligoG conjugates. When the ester-linked OligoG–colistin conjugate was contained
in the IC, diffusion of colistin was more pronounced than when the amide-linked conjugate was
tested, presumably due to the unstable nature of the ester bond. A. baumannii is an opportunistic
pathogen that can causes serious infections often associated with multidrug resistant strains and
has an 8.4–36.5% mortality rate [54]. In the present TTK study, although colistin sulphate at MIC
(0.25 µg/mL colistin base) and the OligoG–E–colistin conjugate at 2 × MIC (0.25 µg/mL colistin
base) exhibited rapid initial antimicrobial efficacy, marked bacterial re-growth was observed at 24 h.
Previous studies have reported the impact of hetero-resistance of A. baumannii clinical isolates to
colistin that allowed significant bacterial re-growth at 24 h at 32 × MIC [55] and 64 × MIC [56].
The reduction of viable bacterial counts by <3 log10 CFU/mL compared to the initial inoculum
was indicative of bacteriostatic activity only. Similarly, bacteriostatic activity of colistin, at its MIC,
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towards A. baumannii clinical isolates has been demonstrated, indicating a 2-fold decrease in CFU/mL at
4–6 h post-dose [57]. Importantly, previous studies saw significant bactericidal activity of colistin when
carbapenem-resistant A. baumannii isolates were treated with higher concentrations of the antibiotic
(≥4 ×MIC) [58]. Observations in the present study support the clinical limitations of conventional
colistin therapy, due to concentration-dependent nephrotoxicity, which may limit the optimal dosing
and efficacy of the antibiotic.
The findings of this study indicate that the ester-linked OligoG–colistin conjugate could be a
suitable alternative to conventional colistin, as it demonstrated equivalent antimicrobial effectiveness
(0.25 µg/mL colistin base) but exhibited significantly lower cytotoxicity in human kidney cells.
Following systemic administration of colistimethate sodium (Colomycin®; prodrug of colistin),
the plasma colistin concentration at steady-state is 0.5–4 µg/mL [59]. Clinically, nephrotoxicity is an
important limiting factor to colistin dosing, therefore, a plasma concentration of 2 µg/mL is desirable to
target bacterial pathogens with MIC values ≤1 µg/mL [60]. To avoid acute kidney injury, a maximum
plasma concentration of 2.42 µg/mL is recommended [61]. Yet, the clinical susceptibility breakpoint
for colistin against Acinetobacter spp. is 2 µg/mL [48,49], which gives it a narrow therapeutic index
in vivo. Due to the EPR effect, OligoG–E–colistin conjugates are expected to accumulate within infected
tissues, so higher antibiotic concentrations (>0.25 µg/mL colistin base, equivalent to >2 ×MIC) could
theoretically be achieved much quicker than with the unmodified antibiotic. Sustained release over 48 h
and concentration-dependent antibacterial efficacy of colistin has been achieved using dextrin–colistin
conjugates [32]. In that study, colistin was covalently linked to dextrin through an amide bond,
so “unmasking” of antibiotic relied on α-amylase-mediated degradation of the polymer. The fact
that the OligoG–A–colistin conjugate did not show any antimicrobial effect in the PK–PD model in
this study could be attributed to the absence of alginate lyase in the culture medium or the presence
of residual saccharides attached to colistin which would not be present on antibiotic released from
the ester-linked conjugates. Recently, it has been demonstrated that, even after complete amylase
degradation of dextrin in amide-linked dextrin-colistin conjugates, the colistin molecule was still
attached to at least one linker with varying lengths of glucose units [18]. These findings suggest that
complete “unmasking” or release of colistin is a pre-requisite for reinstatement of antibiotic activity.
Importantly, the therapeutic benefits of OligoG–colistin conjugates might have been
underestimated by the in vitro assays. Passive accumulation of conjugates at sites of in vivo bacterial
infection due to the EPR effect, alongside the local reduced pH, reactive oxygen species and esterase
activity as well as alginate lyase could all promote the controlled release of the drug from the polymer,
and might further enhance the efficacy of the drug in vivo and thus, reduce the doses required to
eradicate infection.
5. Conclusions
This study has established, for the first time, the potential therapeutic benefits of using OligoG
conjugation to reduce antibiotic toxicity, while maintaining antimicrobial activity against MDR
Gram-negative bacterial pathogens. These studies also demonstrate that complete detachment of the
polymer from the bioactive compound is required to restore its full biological efficacy, with residual
sugars shown to impede complete regeneration of activity. As OligoG has been shown to enhance the
antimicrobial activity of macrolides, tetracyclines and β-lactams antibiotics, against a range of MDR
Gram-negative bacteria [20], OligoG conjugation might also improve the pharmacokinetics of other toxic,
water-insoluble or otherwise undeliverable drugs. Polymer conjugates like the OligoG–polymyxins
offer a novel approach to repurpose “old” antibiotics into safer, less toxic bi-functional compounds to
meet the increasingly urgent need for new antimicrobial therapies.
Supplementary Materials: The following are available online at http://www.mdpi.com/1999-4923/12/11/1080/s1,
Figure S1: Size exclusion chromatography with multi-angle light scattering detection (SEC-MALS) analysis of
OligoG-conjugates (three different batches of OligoG–A–colistin (OAC) and one batch of OligoG–E–colistin (OEC)),
showing overlaid refractive index chromatograms and corresponding Mw-time calibration lines. The injected
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mass was 250 µg for all samples. Abbreviations: A, amide; E, ester, Figure S2: SEC-MALS analysis of OligoG
in the absence and presence of 10% w/w colistin, showing that they do not form strong complexes since the
elution profile is identical, Figure S3: Diffusion-ordered spectroscopy (DOSY) of (a–c) three different batches of
OligoG–A–colistin conjugates and (d) one batch of OligoG–E–colistin conjugate. The assignment of the unique
signals for OligoG and colistin is indicated at the top of each panel and the red lines indicate the average diffusion
coefficients of the molecules, Figure S4: Drug release of OligoG–polymyxin conjugates in phosphate buffered
saline (PBS) at pH 5, pH 7 or pH 7 containing alginate lyase (AlgL). (a) Content of free polymyxin and (b)
change in molecular weight were determined by fast protein liquid chromatography (FPLC) and size exclusion
chromatography with refractive index detection (SEC-RI), respectively, over 48 h incubation. Abbreviations:
A, amide; E, ester, Table S1: Gram-negative bacterial isolates used for characterisation of OligoG–polymyxin
conjugates, Table S2: Physicochemical characteristics and batch details of OligoG–polymyxin conjugates used in
this study, Table S3: Weight and number average molecular weights of OligoG and OligoG–colistin conjugates,
Table S4: Selectivity index (SI) values of OligoG–polymyxin conjugates against a range of Gram-negative bacterial
pathogens, Table S5: Microbiological efficacy (MICs) of OligoG–colistin conjugates in the presence of alginate
lyase in Mueller–Hinton (MH) broth or after pre-incubation with alginate lyase against Gram-negative bacterial
pathogens, Table S6: Microbiological efficacy (MICs) of polymyxins and antibiotic conjugates in the absence
and presence of mucin against Gram-negative bacterial pathogens, Table S7: Comparison of the effect of growth
medium (AS medium and MH broth) on antimicrobial activity (MIC determinations) of polymyxins and antibiotic
conjugates, Table S8: Fractional inhibitory concentration index (FICI) values of OligoG–colistin conjugates or
colistin in combination with azithromycin dihydrate, Methods: NMR spectroscopy.
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